(Reuters) - U.S. drug reviewers said the serious heart, lung and liver side effects of Onyx Pharmaceuticals Inc's carfilzomib drug may outweigh the experimental drug's benefits for patients with a type of blood cancer.
JUMP
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment